CEOS: AI 评分 68/100 — AI 分析 (4月 2026)

Psykey, Inc. focuses on researching, developing, and commercializing entheogenic, adaptogenic, and nootropic ingredients. The company targets functional product lines and technologies for the psychedelic market, offering products like mushroom coffees, teas, and supplements.

Key Facts: AI Score: 68/100 Sector: Healthcare

公司概况

概要：

Psykey, Inc., formerly CeCors, Inc., operates in the healthcare sector, focusing on entheogenic and adaptogenic ingredients for functional products. The company develops technologies for targeted delivery of entheogen-based therapeutics and offers retail products like mushroom-infused beverages and supplements, positioning itself in the emerging psychedelic market.

CEOS是做什么的？

Psykey, Inc., founded in 2002 and based in Toronto, Canada, is a healthcare company engaged in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients. These ingredients are used in their functional product lines, which aim to improve and optimize life. The company also develops technologies focused on the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the burgeoning psychedelic market. Psykey's retail offerings include functional mushroom coffees and teas, oral supplements, and single-serve drink mixes. Formerly known as CeCors, Inc., the company rebranded as Psykey, Inc. in August 2021, signaling its strategic shift towards psychedelic and functional ingredients. This transformation reflects the company's commitment to innovation in the health and wellness sector, particularly in areas related to mental health and cognitive enhancement. Psykey's focus on research and development aims to create novel therapeutic solutions and consumer products that leverage the potential benefits of entheogens and adaptogens.

CEOS的投资论点是什么？

Psykey, Inc. presents a speculative investment opportunity within the emerging psychedelic therapeutics and functional ingredients market. The company's focus on developing technologies for targeted delivery of entheogen-based therapeutics could be a key value driver, contingent on successful research and regulatory approvals. With a market capitalization of $0.00B and a negative P/E ratio of -2.38, the company's financial performance is currently weak, indicated by a negative profit margin of -5.6%. However, a high gross margin of 99.6% suggests potential for profitability if sales volume increases. Key growth catalysts include successful product launches and advancements in their therapeutic technologies. The investment thesis hinges on Psykey's ability to capitalize on the growing interest in psychedelic medicine and functional foods.

CEOS在哪个行业运营？

Psykey, Inc. operates within the rapidly evolving market for functional foods and psychedelic therapeutics. The industry is experiencing increased interest in alternative treatments for mental health and wellness, driving demand for products containing entheogenic and adaptogenic ingredients. This market is characterized by intense competition, with numerous companies vying for market share. Psykey's focus on research and development aims to differentiate itself through innovative formulations and targeted delivery technologies. The company's success will depend on its ability to navigate regulatory hurdles and establish a strong brand presence in a competitive landscape.

Medical - Instruments & Supplies

Healthcare

CEOS有哪些增长机遇？

Expansion of Product Lines: Psykey can capitalize on the growing demand for functional foods and beverages by expanding its product lines to include a wider range of mushroom-infused products and supplements. The global functional food market is projected to reach $267.92 billion by 2027, offering a substantial opportunity for Psykey to increase its market share through innovative product development and targeted marketing campaigns. Timeline: 1-2 years.
Development of Entheogen-Based Therapeutics: Psykey's research and development efforts in entheogen-based therapeutics could lead to the development of novel treatments for mental health disorders. The psychedelic therapeutics market is projected to reach $10.75 billion by 2027, presenting a significant growth opportunity for Psykey if it can successfully navigate regulatory approval processes and commercialize its therapeutic technologies. Timeline: 3-5 years.
Strategic Partnerships and Collaborations: Psykey can accelerate its growth by forming strategic partnerships with research institutions, pharmaceutical companies, and distribution networks. Collaborations can provide access to new technologies, funding, and market channels, enabling Psykey to expand its reach and accelerate the development and commercialization of its products. Timeline: Ongoing.
Geographic Expansion: Psykey can expand its geographic presence by targeting new markets in North America, Europe, and Asia. The global market for functional foods and psychedelic therapeutics is growing rapidly, offering opportunities for Psykey to establish a presence in new regions and increase its customer base. Timeline: 2-3 years.
Intellectual Property Protection: Psykey can strengthen its competitive advantage by securing intellectual property protection for its innovative formulations and technologies. Patents and trademarks can provide exclusive rights to its products and processes, preventing competitors from replicating its offerings and enhancing its market position. Timeline: Ongoing.

Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
P/E Ratio of -2.38 reflects current losses, suggesting the company is in a growth phase and not yet profitable.
Gross Margin of 99.6% demonstrates strong pricing power and efficient cost management in its product lines.
Profit Margin of -5.6% highlights the need for improved operational efficiency and increased sales to achieve profitability.
Beta of 0.63 suggests the stock is less volatile than the overall market, potentially offering some stability in a turbulent sector.

CEOS提供哪些产品和服务？

Researches and develops entheogenic ingredients.
Researches and develops adaptogenic ingredients.
Researches and develops nootropic ingredients.
Formulates functional product lines.
Develops technologies for targeted delivery of entheogen-based therapeutics.
Offers functional mushroom coffees and teas.
Offers oral supplements.
Offers single-serve drink mixes.

CEOS如何赚钱？

Develops and sells functional food and beverage products containing mushroom extracts and other adaptogens.
Researches and develops technologies for the delivery of entheogen-based therapeutics.
Generates revenue through direct-to-consumer sales and partnerships with retailers.

Health-conscious consumers seeking functional food and beverage products.
Individuals interested in the potential benefits of adaptogens and nootropics.
Patients seeking alternative treatments for mental health disorders (future).

Proprietary formulations of entheogenic, adaptogenic, and nootropic ingredients.
Development of targeted delivery technologies for entheogen-based therapeutics.
Early mover advantage in the emerging psychedelic market.

什么因素可能推动CEOS股价上涨？

Upcoming: Potential regulatory approvals for entheogen-based therapeutics could significantly boost investor confidence and market valuation.
Ongoing: Expansion of product lines and market reach in the functional food and beverage sector.
Ongoing: Strategic partnerships with research institutions and pharmaceutical companies to accelerate development and commercialization.

CEOS的主要风险是什么？

Potential: Regulatory hurdles and uncertainty surrounding entheogen-based products could delay or prevent commercialization.
Potential: Intense competition in the functional food and psychedelic markets could limit market share and profitability.
Ongoing: Limited market capitalization and negative profit margin pose financial sustainability risks.
Ongoing: Dependence on research and development for future growth exposes the company to technological and clinical trial risks.

CEOS的核心优势是什么？

Focus on emerging markets of entheogenic and adaptogenic ingredients.
Development of innovative delivery technologies.
Diverse product lines including functional beverages and supplements.
High gross margin.

CEOS的劣势是什么？

Limited market capitalization.
Negative profit margin.
Reliance on research and development for future growth.
Limited brand recognition.

CEOS有哪些机遇？

Expansion into new geographic markets.
Strategic partnerships with research institutions and pharmaceutical companies.
Increasing consumer demand for functional foods and alternative therapies.
Potential for regulatory approval of entheogen-based therapeutics.

CEOS面临哪些威胁？

Intense competition in the functional food and psychedelic markets.
Regulatory hurdles and uncertainty surrounding entheogen-based products.
Potential for adverse side effects from entheogenic ingredients.
Fluctuations in raw material costs.

CEOS的竞争对手是谁？

Atlas Corp — Focuses on cannabis and hemp-based products. — (ATTBF)
Harvest One Cannabis Inc — Develops and markets cannabis-derived health and wellness products. — (HADV)
Healthways Inc — Offers well-being improvement solutions. — (HDVY)
Inspiraderm Inc — Develops innovative dermatological treatments. — (INSD)
Isolife Corp — Focuses on developing and marketing cannabinoid-based products. — (ISOLF)

Key Metrics

MoonshotScore: 68/100

Company Profile

CEO: Michael Maher
Headquarters: Toronto, CA
Employees: 6
Founded: 2006

AI Insight

AI analysis pending for CEOS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Psykey, Inc. do?

Psykey, Inc. is a healthcare company that researches, develops, and commercializes entheogenic, adaptogenic, and nootropic ingredients for functional product lines. They focus on technologies for targeted delivery of entheogen-based therapeutics, aiming to improve mental health and cognitive function. Their retail products include functional mushroom coffees and teas, oral supplements, and single-serve drink mixes, positioning them in the emerging psychedelic and functional food markets. The company seeks to capitalize on the growing interest in alternative treatments and wellness solutions.

What do analysts say about CEOS stock?

As of March 17, 2026, there is no available analyst coverage for CEOS stock. Given its OTC Other listing and micro-cap status, the stock may not be actively tracked by major research firms. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include market capitalization, P/E ratio, gross margin, and profit margin.

What are the main risks for CEOS?

The main risks for Psykey, Inc. include regulatory uncertainty surrounding entheogen-based products, intense competition in the functional food and psychedelic markets, limited market capitalization, and negative profit margin. The company's dependence on research and development for future growth exposes it to technological and clinical trial risks. Additionally, its OTC listing on the OTC Other tier carries inherent risks related to liquidity, transparency, and regulatory oversight. Investors should carefully consider these factors before investing in CEOS.